SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Call Transcript

Brian Adams: Okay. And then just a secondary question. With the STOMP trial, which has been going on for a good 18-odd months or so, is it – not to put words in your mouth, do you feel somewhat frustrated of the results and how long some of the – how long this has taken as far as getting results? And any kind of color or comment from the FDA on this?

Diem Nguyen: From the STOMP trial perspective, as noted, it is sponsored by the NIAID and has enrolled over 350 patients as of April. So there has been a substantial increase from what we noted from our last call. April 2024 was the highest recruitment month to date for the STOMP trial, which is currently enrolling about roughly 50 patients per month. So we’re not at all frustrated with the pace given the fact that we’re seeing high recruitment. As it relates to current FDA guidance on target enrollment, the study will be fully enrolled in 2025. And we would caution that there’s a lot of variables that will impact timing until recruitment is complete. However, we are working closely with our partners to file with FDA as soon as we can.

Brian Adams: Okay. Great. Thank you for the question and your time. Thank you. Great quarter. Appreciate it.

Diem Nguyen: Thank you.

Operator: Thank you. Ms. Diem Nguyen, there are no further questions at this time. Please proceed.

Diem Nguyen: Thanks, operator. I’d like to thank everyone for making time to join us on today’s call and for your ongoing interest in SIGA. We really look forward to speaking to you again in our second quarter call. Have a good rest of the evening.

Operator: Thank you. This concludes today’s call. Thank you for participating. You may all disconnect.